EBMT 2026 | The role and importance of accreditation in the changing landscape of cellular therapies in Europe
In this video, Christian Chabannon, MD, PhD, Paoli-Calmettes Institute, Marseille, France, briefly discusses the importance of JACIE accreditation in the transplant and cellular therapy field, highlighting the challenge of adapting accreditation as the indications for cellular therapies expand. This interview took place at the 52nd Annual Meeting of the EBMT in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Well in Europe, JACIE has been around for more than a quarter of a century now. The first accreditations were delivered in 2002 and JACIE is a system that guarantees that each individual involved in transplant or cellular therapy has the necessary skills to properly care for patients but also ensures that there is proper coordination between the different categories of professionals as well as different hospital infrastructures...
Well in Europe, JACIE has been around for more than a quarter of a century now. The first accreditations were delivered in 2002 and JACIE is a system that guarantees that each individual involved in transplant or cellular therapy has the necessary skills to properly care for patients but also ensures that there is proper coordination between the different categories of professionals as well as different hospital infrastructures. So this is paradigmatic of a quality management system that helps improve the safety and efficacy of these treatments. The challenge that JACIE is facing now is the augmentation of the number of indications for cellular therapies, including beyond the historical field of hematology, and how we will deal with these activities that may take place in non-transplant departments in various hospitals.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Honoraria or consultation fees: BMS, Kite/Gilead, Jazz, Miltenyi Biotec, Novartis.
